drugset / Trial / NCT03716622

A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication

NCT03716622

Phase 4 Completed 350 enrolled Shandong University
RandomizedCrossoverOpen-labelTreatment

Summary

We aim to assess and compare the effectiveness of clarithromycin- and furazolidone-based regimens as primary therapies in eradicating H. pylori.

Timeline

Start
2018-07-31
Primary completion
2019-08-31
Completion
2019-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clarithromycin Small molecule 500 mg Oral
Subject Furazolidone Small molecule 100 mg Oral